An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?

A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Max Planck Institute for Innovation and Competition. Study and annexes on the legal aspects of Supplementary Protection Certificates in the EU. https://ec.europa.eu/docsroom/documents/29524 (2018).

  2. 2

    Copenhagen Economics. Study of the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe. https://ec.europa.eu/docsroom/documents/29521 (May 2018).

  3. 3

    European Commission. Proposal for a regulation of the European Parliament and of the Council amending Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products. COM/20182018/317 final – 2018/0161(COD). https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=COM:2018:317:FIN (2018).

  4. 4

    European Commission. Impact assessment accompanying the document “Proposal for a Regulation of the European Parliament and of the Council amending Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products.” https://ec.europa.eu/docsroom/documents/29463 (2018).

  5. 5

    EFPIA. EFPIA statement on the Commission's proposal to introduce an SPC manufacturing waiver, weakening Europe's knowledge based economy. https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/28052018-efpia-statement-on-the-commission-s-proposal-to-introduce-an-spc-manufacturing-waiver-weakening-europe-s-knowledge-based-economy/ (2018).

  6. 6

    Medicines for Europe. Risk that European Council will “neuter” SPC manufacturing waiver and give foreign (non-EU) manufacturers strong advantage over EU-based manufacturers. https://www.medicinesforeurope.com/news/risk-that-european-council-will-neuter-spc-manufacturing-waiver-and-give-foreign-non-eu-manufacturers-strong-advantage-over-eu-based-manufacturers/ (2018).

  7. 7

    Agreement on trade-related aspects of intellectual property rights (15 April 1994). Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197 (1994).

  8. 8

    Patent Law Amendments Act of 1984, Pub. L. No. 98–622 (1984) (codified at 35 U.S.C. § 271(f)).

  9. 9

    WesternGeco LLC v. ION Geophysical Corp., No. 16–1011, 138 S. Ct. 2129 (2018).

Download references

Acknowledgements

The authors gratefully acknowledge B. Bergsson for research support. This research was supported by a Novo Nordisk Foundation grant for a scientifically independent Collaborative Research Programme (grant number NNF17SA027784). J.J.D. and A.S.K. receive research support from the Laura and John Arnold Foundation, the Harvard Program in Therapeutic Science, and the Engelberg Foundation. The funders had no role in the conception, preparation, or approval of the manuscript, or in the decision to submit the manuscript for publication.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jonathan J Darrow.

Ethics declarations

Competing interests

T.M. is a member of the Expert Board for Copenhagen Economics' “Study on the economic impact of SPCs, pharmaceutical incentives and rewards in Europe” (European Commission (DG GROW), Tender reference number 590/PP/GRO/SME/16/F/121).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Minssen, T., Kesselheim, A. & Darrow, J. An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?. Nat Biotechnol 37, 21–22 (2019). https://doi.org/10.1038/nbt.4324

Download citation

Further reading